Acrivon Therapeutics, Inc.·4

Oct 3, 4:28 PM ET

Mirza Mansoor Raza 4

4 · Acrivon Therapeutics, Inc. · Filed Oct 3, 2025

Insider Transaction Report

Form 4
Period: 2025-10-01
Mirza Mansoor Raza
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-10-01+225,000225,000 total
    Exercise: $1.81Exp: 2035-09-30Common Stock (225,000 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the shares subject to the option vest on November 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Documents

1 file
  • 4
    form4.xmlPrimary